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Abstract
GrB/scFvMEL, a fusion protein composed of human
granzyme B (GrB) and the single-chain antibody
scFvMEL, targets melanoma gp240 antigen and exerts
impressive cytotoxic effects by inducing apoptosis.
We evaluated the effects of GrB/scFvMEL on chemo-
therapy, radiation therapy, metastasis in vitro, and the
growth of human melanoma A375 xenograft tumors
in nude mice. GrB/scFvMEL showed synergistic cyto-
toxicity when coadministered with doxorubicin, vincris-
tine or cisplatin, and additive effects, in combination
with etoposide or cytarabine. Optimal cytotoxic effects
were obtained when cells were treated first with GrB/
scFvMEL followed by exposure to the agent (rather
than the reverse). Pretreatment of A375 cells with GrB/
scFvMEL significantly sensitized melanoma cells to
ionizing radiation assessed using a clonogenic sur-
vival assay. Subtoxic doses of GrB/scFvMEL inhibited
the invasion of A375 cells into Matrigel. GrB/scFvMEL
(37.5 mg/kg) was administered intravenously to nude
mice bearing A375 tumors. Saline-treated tumors in-
creased 24-fold, whereas tumors treated with GrB/
scFvMEL showed a significant tumor growth delay in-
creasing four-fold. Tumor tissue displayed an increase
in apoptotic nuclei compared to control. Thus, the tar-
geted delivery of GrB to tumors may have a significant
potential for cancer treatment. Targeted therapeutic
agents specifically designed to impact cellular apopto-
tic pathways may represent a novel class of therapeu-
tic agents.
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Introduction
Disseminated melanoma is presently not curable [1] using
current clinical tools, and the metastatic spread of mela-
noma appears to directly involve alterations in cellular
apoptotic pathways [2,3]. Traditional chemotherapy is an ex-
tremely ineffective means of treating malignant melanoma due
to the inherent drug-resistant characteristic of this disease. The
reasons for the chemoresistant phenotype in human mela-
noma are not well understood and are probably multifactorial.
However, a growing understanding of the molecular events that
mediate tumor growth and metastatic spread has led to the
development of rationally designed targeted therapeutics that
offer a dual hope of maximizing antitumor efficacy and mini-
mizing toxicity to normal tissues [4]. Approaches to directly
modulate cellular apoptosis pathways are of particular interest
in terms of new drug developments in melanoma. The acti-
vation of apoptotic mechanisms in melanoma cells has been
directly implicated in the response of patient tumors to che-
motherapy, response to radiotherapy, and in cells’ propensity
to metastasize [5–8].
The high-molecular-weight melanoma-associated glyco-
protein gp240 has previously been demonstrated in a majority
(80%) of melanoma cell lines and fresh tumor samples [9].
Antibodies targeting the gp240 antigen, such as ZME-018 and
9.2.27, have been extensively studied in melanoma patients
and have demonstrated an impressive ability to localize in me-
tastatic tumors after systemic administration [10–13]. ZME-
018 antibody possesses high specificity for melanoma and is
minimally reactive with a variety of normal tissues, making it
a promising candidate for further study [11,12,14,15].
Recombinant single-chain Fv antibody (scFv)–based
agents have been used in preclinical studies for cell-targeted
delivery of cytokines [16] and intracellular delivery of highly
cytotoxic n-glycosidases such as recombinant gelonin (rGel)
toxin [17]. The smaller size of these antibody fragments may
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allow better penetration into tumor tissues, improved phar-
macokinetics, and reduction in the immunogenicity observed
with intravenously administered murine antibodies.
Initially, to target melanoma cells, we chose a recombi-
nant single-chain antibody scFvMEL, which retains the same
binding affinity and specificity of the parental ZME-018 anti-
body recognizing the surface domain of the gp240 antigen.
The scFvMEL antibody has been used extensively in our lab-
oratory to target gp240-bearing cells in vitro and using xeno-
graft models [13,15,17–21]. This antibody binds to target
cells and is efficiently internalized, making this an excellent
carrier for the delivery of toxins or other cytotoxic payloads.
Cytotoxic T lymphocyte (CTL) and natural killer (NK) cell
types destroy tumor cells by direct physical delivery of
human granzyme B (GrB), a serine protease, thereby induc-
ing apoptosis. This is one of the major mechanisms in cel-
lular immune response [22]. CTL granules contain perforin
(PFN), a pore-forming protein, and a family of serine pro-
teases termed granzymes. In CTL-mediated cytolysis, PFN
is initially released and inserts into the target cell mem-
branes, where it polymerizes to form transmembrane pores
[23], which facilitates the access of NK- or CTL-released GrB
to the target cell cytoplasm. Once delivered to the cyto-
plasm, GrB induces apoptosis by directly activating cas-
pases and inducing rapid DNA fragmentation [24]. GrB
can cleave many procaspases in vitro including caspases
3, 7, 6, 8, and 9 [25]. Some studies have shown that GrB
activated cell death pathways through cleavage of Bid and
activation of the mitochondrial death pathway in intact cells
[26]. In addition to caspase-mediated cytotoxic events, GrB
can also rapidly translocate to the nucleus and cleave
poly(ADP-ribose) polymerase (PARP) and nuclear matrix
[27], subsequently inducing cell death through caspase-
independent pathway.
Because almost all cells contain mechanisms responsible
for mediating cell death (apoptosis), we propose that the tar-
geted delivery of GrB protein to the interior of cells will result
in cell death through apoptotic mechanisms, assuming that
sufficient quantities of active enzyme are successfully de-
livered to the appropriate subcellular compartment.
We previously described [18] a novel recombinant fusion
construct designated as GrB/scFvMEL, composed of human
GrB and the anti-gp240 single-chain antibody scFvMEL. This
construct was shown to contain enzymatically active GrB,
and we demonstrated that the construct specifically bound
to human A375-M melanoma cells. In addition, we demon-
strated that this agent efficiently delivered GrB to the cyto-
plasm of melanoma target cells. The cytotoxic effects of the
fusion construct on A375-M cells were impressive, and the
observed apoptotic effects were shown to be mediated by
caspase-dependent and caspase-independent pathways. In
the current study, we further investigated the proapoptotic
effects of GrB/scFvMEL on different melanoma cell lines,
and we examined the impact of targeted apoptosis on the
response of tumor cells to chemotherapeutic agents, ionizing
radiation, and metastatic potential. In addition, we examined
the in vivo antitumor activity of this novel fusion construct
against A375 melanoma tumor xenografts. Our data strongly
indicate that GrB/scFvMEL demonstrates impressive anti-
tumor activity in vitro and in vivo, enhances the sensitivity of
human melanoma cells to various chemotherapeutic agents,
sensitizes tumor cells to ionizing radiation, and inhibits tumor
cell invasion of Matrigel. The targeted delivery of human pro-




Human melanoma cells were obtained from Dr. I. J. Fidler
(M. D. Anderson Cancer Center, Houston, TX). TXM-1 and
TXM-18L cells were cultured in minimum essential medium
(MEM), and A375-M cells were cultured in Dulbecco’s MEM
containing 10% fetal bovine serum (FBS), with added so-
dium pyruvate (100 mM), nonessential amino acids (10 mM),
glutamine (200 nM), and MEM vitamins. MEL-526 cells were
cultured in RPMI 1640 containing 10% FBS. All cells were
routinely grown at a density of 7  106 cells per T-75 flask,
subcultured twice per week, and were routinely tested and
found to be free of Mycoplasma contamination using the
Gen-Probe assay kit (Gen-Probe, Inc., San Diego, CA).
Expression and Purification of GrB/scFvMEL
The construction, expression, and purification of GrB/
scFvMEL have been previously described [18]. The fusion
protein was stored in sterile 150 mM NaCl at 20jC.
Antigen gp240 Staining and Fluorescence-Activated
Cell Sorter (FACS) Analysis
Samples consisting of 1  106 cells were first treated with
ZME-018 IgG2a for 20 minutes at 4jC, then stained with
allophycocyanin (APC)–conjugated goat anti-mouse anti-
body (BD Immunocytometry System, San Jose, CA) for an-
other 20 minutes at 4jC, both resuspended in 100 ml of FACS
staining buffer [2% fetal calf serum/Dulbecco’s phosphate-
buffered saline (DPBS)]. As negative staining control, cells
were stained with an isotype-matched control antibody of ir-
relevant specificity (mouse IgG2a; PharMingen, San Diego,
CA) at the same concentration as that of the antibody against
gp240. Following staining, cells were washed twice with
DPBS, resuspended in 500 ml of 1% paraformaldehyde so-
lution, and stored on ice in the dark. FACS analysis was
performed immediately thereafter on a FACS Caliber cytom-
eter (Becton Dickinson, San Jose, CA). APC fluorescence
was detected in an FL-4 channel. For each cell line, 10,000
events were acquired. Analysis was performed with the
CellQuest Pro software (Becton Dickinson).
Enzyme-Linked Immunosorbent Assay (ELISA) Assays
Ninety-six-well ELISA plates containing adherent mela-
noma cells (5  104 cells/well) were used as described
previously [19]. To detect the binding activity of GrB/
scFvMEL, cells were incubated with purified GrB/scFvMEL
at various concentrations for 1 hour at room temperature
(RT). After they were washed, the cells were incubated with
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rabbit anti-scFvMEL antibody, followed by the addition of
goat anti-rabbit/HRP conjugate (HRP-GAR) antibody. Fi-
nally, the substrate (2,2V-azino-bis-3-ethylbenzthiazoline-6-
sulfonic acid, ABTS) solution containing 1 ml/ml 30% H2O2
was added to the wells. Absorbance at 405 nm was mea-
sured after 30 minutes.
Internalization Analysis by Immunofluorescence
Cells were plated into 16-well chamber slides (Nalge Nunc
International, Naperville, IL) at a density of 1 104 cells/well.
Cells were treated with GrB/scFvMEL (40 nM) for 1 hour.
Proteins binding to the cell surface were removed by brief
incubation with glycine buffer (0.5 M NaCl and 0.1 M glycine,
pH 2.5) followed by immunofluorescent staining, as de-
scribed previously [18]. Briefly, cells were fixed in 3.7%
formaldehyde and permeabilized in 0.2% Triton X-100. Sam-
ples were blocked with 3% bovine serum albumin (BSA), in-
cubated with goat anti-GrB monoclonal antibody (mAb), and
then incubated with FITC-coupled anti-goat IgG and pro-
pidium iodide (PI; 2.5 mg/ml). The slides were mounted with
DABCO containing 1 mg/ml PI and analyzed under a Nikon
Eclipse TS-100 fluorescence microscope (Tokyo, Japan).
Photographs were taken with a scope-mounted camera.
In Vitro Cytotoxicity Assays
To examine the cytotoxicity of GrB/scFvMEL or MEL/sFv/
rGel, melanoma cells were plated on 96-well plates at a den-
sity of 4  103 cells/well and allowed to adhere for 24 hours
at 37jC in 5%CO2. After 24 hours, the mediumwas replaced
with one that contained various concentrations of fusion pro-
teins. The effects on the growth of tumor cells in culture were
determined by crystal violet (0.5% in 20% methanol) staining
and solubilized with Sorenson’s buffer (0.1 M sodium citrate,
pH 4.2, in 50% ethanol), as described previously [19]. Per-
cent control refers to the percentage of cells in drug-treated
wells compared to that of control (untreated) wells.
Combination Studies of GrB/scFvMEL with
Chemotherapeutic Agents
Cells in exponential growth phase were plated into 96-well
plates. After 24 hours, the cells were treated with a drug-
containing medium. At the end of the indicated incubation
period, growth inhibition was assessed by crystal violet stain-
ing. IC25 doses of either GrB/scFvMEL or chemotherapeutic
agents have been used in combination studies. To determine
the effects of sequencing, cells were treated with two differ-
ent sequences: sequence I—cells were pretreated with a
chemotherapeutic agent for 6 hours, followed by coadminis-
tration with GrB/scFvMEL for 72 hours; sequence II—cells
were pretreated with GrB/scFvMEL for 6 hours, followed
by coadministration with a chemotherapeutic agent for
72 hours. Chemotherapeutic agents include doxorubicin
(DOX), vincristine (VCR), etoposide (VP-16), cisplatin
(CDDP), cytarabine (Ara C), and 5-fluorouracil (5-FU).
Clonogenic Survival Assay
The effectiveness of the combination of GrB/scFvMEL
and ionizing radiation was assessed by clonogenic assay.
Melanoma cells were either treated with PBS or pretreated
with GrB/scFvMEL (10 nM) for 16 hours. Then, cells were ir-
radiated with various doses of ionizing radiation and then
processed for clonogenic cell survival assay. Following treat-
ment, cells were trypsinized and counted. Known numbers
were replated in triplicate and returned to the incubator to al-
lowmacroscopic colony development. Colonies were stained
with crystal violet solution and counted afterf14 days. The
percentage of plating efficiency and the fraction surviving a
given treatment were calculated based on the survival of
nonirradiated cells treated with the agent in question.
Tumor Cell Invasion (Matrigel) Assay
Subconfluent A375DR cells were collected by trypsiniza-
tion, resuspended in culture medium, and seeded in 20 ml
(100,000 cells) on the lid of a culture dish. The lid was then
placed on a dish filled with 2 ml of culture medium and
incubated at 37jC for 48 hours. Matrigel solution (100 ml,
2.7 mg/ml) was pipetted onto the bottom of a 24-well culture
dish and left to set at 37jC. Cell aggregates were transferred
over the cushion and then overlaid with an additional 100 ml
of Matrigel. The aggregates into Matrigel were covered with
400 ml of culture medium in the absence or in the presence of
GrB/scFvMEL (50 nM). The aggregates were then observed
daily under a light microscope; at the end of the incubation
time, pictures of the aggregates were taken. The densities of
cells invading into Matrigel surrounding the aggregates were
analyzed by AlphaEaseFC software (Alpha Innotech, San
Leandro, CA), and percent invasion was calculated based
on the cell densities of two groups and standardized by the
value of the nontreatment control group as 100% invasion.
Animal Model Studies
A375-M xenograft model and therapy study design Athy-
mic (nu/nu) mice, 4 to 6 weeks old, were obtained from
Harlan Sprague Dawley (Indianapolis. IN). The animals were
maintained under specific pathogen-free conditions and
were used at 6 to 8 weeks of age. Animals were injected
subcutaneously (right flank) with 3  106 log-phase A375-M
melanoma cells, and tumors were allowed to establish. Once
tumors had reached a measurable size (f30–50 mm3), ani-
mals were treated through the intravenous tail vein with either
saline (control) or GrB/scFvMEL fusion construct. Fusion
protein GrB/scFvMEL was given intravenously in a 0.2-ml vol-
ume. Doses mentioned in this paper are total doses admin-
istered once every other day for five doses. The doses are
reported as milligrams per kilogram based on a mouse aver-
age weight of 20 g. For example, a 20-g mouse given 750 mg
of GrB/scFvMEL would receive a dose of 37.5 mg/kg.
Localization of GrB/scFvMEL after systematic administra-
tion Mice bearing A375-M xenograft tumors were ad-
ministered GrB/scFvMEL (37.5 mg/kg). Twenty-four hours
later, animals were sacrificed; representative tissue sect-
ions were removed; formalin was fixed and stained by hema-
toxylin and eosin (H&E); and immunohistochemical staining
for GrB/scFvMEL was detected by either anti-GrB or anti-
scFvMEL antibody.
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Terminal deoxynucleotidyl transferase–mediated nick end
labeling (TUNEL) assay to detect apoptosis Tumor tissue
sections were stained by TUNEL using an in situ cell death
detection kit (Roche Molecular Biochemicals, Mannheim,
Germany). Briefly, pretreatment of paraffin-embedded tissue
was performed to dewax, rehydrate, and then incubate with
proteinase K followed by fixation and permeabilization. The
tissue sections were incubated with a TUNEL reaction mix-
ture in a humidified chamber for 60 minutes at 37jC, and
then the slides were rinsed thrice with PBS. Samples were
analyzed under a Nikon Eclipse TS100 fluorescent micro-
scope (Tokyo, Japan), and photographs were taken with a
scope-mounted Nikon digital camera.
In vivo cytotoxicity studies
Once tumors’measurable sizes (f30–50mm3) havebeen
established, animals were treated (intravenously through the
tail vein) every other day (five times, 37.5 mg/kg) with either
saline (control) or the GrB/scFvMEL fusion construct. Tumor
growth was monitored by measuring (by caliper) two perpen-
dicular tumor diameters every 2 or 3 days for an additional
28 days, and the volume of the tumor was calculated from
the formula: tumor volume = (width)2  length/2 [28].
Statistical Analysis
Data were analyzed using paired t test (Prism 3.0). Data
are presented as mean ± SE. A difference was regarded as
significant if P < .05.
Results
Antigen gp240 Expression on Melanoma Cells, the
Cell-Binding Activity of the scFvMEL Component of
GrB/scFvMEL, and Internalization of GrB/scFvMEL
To examine the expression of the gp240 antigen on mela-
noma cell lines, melanoma cells consisting of 1  106 were
stained with parental mAb ZME-018 IgG2a that specifically
binds to the gp240 antigen (for 20 minutes) and APC-
conjugated goat anti-mouse antibody (for another 20 min-
utes) at 4jC. As negative staining control, cells were stained
with an isotype-matched control antibody of irrelevant speci-
ficity (mouse IgG2a) at the same concentration as that of the
antibody against gp240. The expression levels of gp240
were indicated as solid lines (by FACS assay) for melanoma
cell lines A375-M, MEL-526, TXM-18, and TXM-1, on which
percent gp240-positive antigens were 98.9%, 97.8%, 40.9%,
and 4.6%, respectively. These data demonstrated that the
gp240 antigen was more highly expressed on A375-M, MEL-
526, and TXM-18 cells; however, there was a very low-level
expression of the gp240 antigen on TXM-1 cells, showing
that the solid lines were overlaid by the dotted lines repre-
senting isotype control (Figure 1).
Because the gp240 antigen highly presents in melanoma
A375-M, MEL-526, and TXM-18L cells, but not in TXM-1
cells, we further examined if the GrB/scFvMEL fusion con-
struct could bind to antigen-positive cells. ELISA was per-
formed to determine the binding activity of the GrB/
scFvMEL fusion construct to melanoma cells. The results
demonstrated that GrB/scFvMEL bound to high-level gp240
antigen–expressing melanoma A375-M, MEL-526, and
TXM-18L cells. Moreover, the binding activity was stronger
in A375-M and MEL-526 cells, followed by TXM-18L cells.
Figure 1. The gp240 antigen is expressed in human melanoma cell lines by
FACS analysis. Melanoma cells consisting of 1  106 cells were first in-
cubated with mAb ZME-018 IgG2a then stained with APC-conjugated goat
anti-mouse antibody, as described under Materials and Methods. As negative
staining control, cells were stained with an isotype-matched control antibody
of irrelevant specificity (mouse IgG2a). Cells were fixed in 1% paraformalde-
hyde solution and stored on ice in the dark after washing. FACS analysis was
carried out, and APC fluorescence was detected by a FACS Caliber cytom-
eter. For each cell line, 10,000 events were acquired. Analysis was performed
with the CellQuest Pro software. Expression of gp240 was indicated as solid
lines for all five melanoma cell lines, which were overlaid by dotted lines re-
presenting isotype control. High-level expression of the gp240 antigen was
demonstrated in all human melanoma cell lines, except TXM-1 cells.
128 Antimelanoma Immunotoxin Containing Granzyme B Liu et al.
Neoplasia . Vol. 8, No. 2, 2006
However, the protein did not bind to TXM-1, in which very low-
level expression of the gp240 antigen was detected by an anti-
scFvMEL rabbit mAb (Figure 2).
The GrB moiety of the fusion construct was efficiently
delivered into the cytosol of gp240 antigen–positive A375-M,
MEL-526, and TXM-18 melanoma cells after treatment with
GrB/scFvMEL for 1 hour, as assessed by immunofluorescent
staining detected using goat anti-GrB antibody (Figure 3).
This effectively demonstrates that the gp240 expression on
the tumor cell surface and the binding of the construct
to the gp240 antigen are responsible for the internalization
of the GrB/scFvMEL fusion construct.
In Vitro Cytotoxicity of GrB/scFvMEL against Various
Melanoma Cell Lines
The cytotoxicity of GrB/scFvMEL was assessed against
log-phase A375-M, MEL-526, TXM-18L, and TXM-1 cells in
culture. Fifty-percent growth-inhibitory effects were found at
concentrations of f30 nM on A375-M cells, of f50 nM on
MEL-526 cells, and of f150 nM on TXM-18L, respectively.
However, no cytotoxic effects were found on TXM-1 cells at
doses of up to 1 mM (Figure 4, Table 1). By comparison, the
cytotoxic effects of GrB/scFvMEL on target cells were simi-
lar to those of the previously described MEL sFv/rGel [17]
(Table 1). These data suggest that there appears to be
a correlation between a high expression of gp240 and an
improved cellular binding of GrB/scFvMEL, resulting in a
comparatively greater cytotoxicity of the fusion protein. In
addition, studies in our laboratory demonstrate that a com-
panion construct MEL sFv/rGel generates a cytotoxic effect
against cells through a necrotic process rather than an
apoptotic process. These comparative studies demonstrate
that the cytotoxic/apoptotic effects of the GrB payload can
match the robust cytotoxic/necrotic effects of rGel-containing
fusion toxins.
Combination Studies of GrB/scFvMEL with Conventional
Chemotherapeutic Agents on A375-M
Because cellular apoptotic processes appear to mediate
response/resistance to chemotherapy [8,29], we next exam-
ined the effects of GrB/scFvMEL in combination with various
chemotherapeutic agents on target cells. Coadministration
of GrB/scFvMEL and various classes of chemotherapeutic
agents to A375-M cells for 72 hours demonstrated syner-
gistic antitumor activity with adriamycin (DOX), VCR or
CDDP, and additive effects, in combination with VP-16, Ara
C, or 5-FU. Pretreatment with GrB/scFvMEL for 6 hours,
followed by coexposure to these chemotherapeutic agents
for 72 hours (sequence II), showed significantly inhibited
growth compared to pretreatment with drugs followed by
Figure 2. GrB/scFvMEL specifically binds to the gp240 antigen–positive
melanoma cell lines, as assessed by ELISA. Ninety-six-well ELISA plates
containing adherent melanoma cells (5  104 cells/well) were blocked by
addition of a solution containing 5% BSA for 1 hour. To detect the binding
activity of GrB/scFvMEL, cells were incubated with purified GrB/scFvMEL at
various concentrations for 1 hour at RT. After washing, the cells were in-
cubated with rabbit anti-scFvMEL antibody, followed by the addition of HRP-
GAR antibody. Finally, the substrate solution ABTS containing 1 l/ml 30%
H2O2 was added to the wells. Absorbance at 405 nm was measured after
30 minutes. GrB/scFvMEL bound to high-level gp240 antigen–expressing
melanoma A375-M, MEL-526, and TXM-18 cells, but not to TXM-1 cells,
which has a very low-level expression of the gp240 antigen.
Figure 3. Internalization of GrB/scFvMEL into A375-M, MEL-526, TXM-18, and TXM-1 cells, as assessed by immunofluorescent staining. Cells were treated with
40 nM GrB/scFvMEL for 1 hour. Molecules bound to the cell surface were removed by brief treatment with glycine buffer (pH 2.5). Cells were fixed in 3.7%
formaldehyde and permeabilized in 0.2% Triton X-100. Samples were blocked with 3% BSA, incubated with goat anti-GrB mAb, and then incubated with FITC-
coupled anti-goat IgG and PI. The slides were mounted with DABCO containing 1 g/ml PI and analyzed under a Nikon Eclipse TS-100 fluorescence microscope.
Internalization of GrB/scFvMEL was observed in the gp240 antigen–positive A375-M, MEL-526, and TXM-18 cells, but not in the gp240 antigen–negative TXM-1
cells. (A) No GrB/scFvMEL treatment control. (B) GrB/scFvMEL treatment for 1 hour.
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coexposure of the fusion construct (sequence I) (Figure 5).
The results indicated that the cytotoxic effects of chemother-
apeutic agents could be markedly enhanced by pretreatment
with GrB/scFvMEL for 6 hours on gp240 antigen–positive
melanoma cells. GrB/scFvMEL was not cytotoxic to antigen-
negative TXM-1 cells at concentrations of up to 1 mM.Wepre-
treated TXM-1 cells with GrB/scFvMEL at 1 mM for 6 hours,
then coadministered various chemotherapeutic agents at
IC50 or IC25 doses. As expected, the cytotoxic effects of var-
ious chemotherapeutic agents were not enhanced by pre-
treatment with GrB/scFvMEL for 6 hours.
Cytotoxicity of GrB/scFvMEL Against A375 Doxorubicin–
Resistant (A375DR) Subline
To examine if cellular resistance to DOX also causes
cross-resistance to the GrB/scFvMEL fusion construct, an
A375DR cell line was first established by continuous expo-
sure of log-phase parental A375-M cells to increasing con-
centrations of DOX, followed by serial dilution and clonal
selection of colonies. One clone designated as A375DR was
400-fold resistant to DOX compared to the parental A375
cell line (IC50 = 200 nM for A375DR versus IC50 = 0.5 nM for
the parental A375 cell line). Treatment of the A375DR cells
demonstrated an IC50 that was only 4.5-fold higher com-
pared to parental A375 cells (IC50 = 63.6 nM for A375DR
versus IC50 = 14.5 nM for A375) (Figure 6, Table 2). Ex-
pression of the gp240 antigen was assessed by ELISA using
the ZME-018 antibody specifically recognizing the gp240
antigen. This study demonstrated that relative gp240 ex-
pression was virtually identical on parental A375 and
A375DR cells (data not shown). The data demonstrated that
Figure 4. The cytotoxic effects of GrB/scFvMEL on the gp240 antigen–
positive melanoma cell lines. Samples (GrB/scFvMEL or MEL sFv/rGel) were
assayed using a standard 72-hour cell proliferation assay with melanoma cell
monolayer and using crystal violet staining, as described under Materials
and Methods. Percent control refers to the percentage of cells in drug-treated
wells compared to that of control (untreated) wells. A 50% growth-inhibitory
effect (IC50) was calculated. The bar chart showed the IC50 value of GrB/
scFvMEL in different melanoma cell lines. GrB/scFvMEL demonstrated cyto-
toxic effects on A375-M, MEL526, and TXM-18L, which expressed high-level
gp240 antigen. However, no cytotoxic effects on TXM-1 cells were found at
doses of up to 1 M.
Figure 5. Pretreatment with GrB/scFvMEL sensitizes various chemother-
apeutic agents. The log-phase gp240 antigen–positive (A375-M) cells were
pretreated (at IC25 doses) with various chemotherapeutic agents for 6 hours,
followed by the addition of GrB/scFvMEL (IC25). The cells were then incu-
bated for a total of 72 hours (sequence I). Alternatively, cells were first treated
with GrB/scFvMEL for 6 hours, and then various chemotherapeutic agents
were added for 72 hours (sequence II). Chemotherapeutic agents include
DOX, VCR, VP-16, cisplantin (CDDP), Ara C, and 5-FU. The coadministration
GrB/scFvMEL and chemotherapeutic agents to A375 cells for 72 hours
demonstrated synergistic antitumor activity with DOX, VCR or CDDP, and
additive effects, in combination with VP-16 or Ara C or 5-FU. Pretreatment
with GrB/scFvMEL for 6 hours, followed by coexposure to these chemo-
therapeutic agents for 72 hours (II), showed significantly inhibited growth as
compared to pretreatment with drugs followed by coexposure to the fusion
construct (I).
Figure 6. Cellular resistance to DOX is associated with marginal cross-
resistance to GrB/scFvMEL. A375DR cells are 400-fold resistant to DOX
compared to parental A375 cells. Log-phase A375DR cells were treated with
various doses of GrB/scFvMEL for 72 hours. Percent control refers to the
percentage of cells in drug-treated wells compared to that of control (un-
treated) wells. A375DR cells demonstrated only a 4.5-fold resistance to GrB/
scFvMEL compared to parental A375 cells (IC50 = 63.6 vs 14.5 nM).
Table 1. Cytotoxicitiy of GrB/scFvMEL Versus MEL sFv/rGel against Various
Human Melanoma Cell Lines*.
Cell Line gp240 Antigen (% Positive)y IC50 (nM)
GrB/scFvMEL scFvMEL/rGel
A375-M 98.9 32.1 ± 7.95 22.03 ± 3.08
MEL-526 97.8 50.0 ± 4.32 40.0 ± 5.55
TXM-18L 40.9 158.3 ± 12.45 144.3 ± 9.56
TXM-1z 4.6 >1000 >1000
*Samples (GrB/scFvMEL and MEL sFv/rGel) were assayed using a standard
72-hour cell proliferation assay and using crystal violet staining. IC50 values
were calculated and demonstrated as mean ± SEM (nM).
yPercent positive FACS analysis.
zNo cytotoxic effect was observed at doses of up to 1000 nM.
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cellular resistance to DOX is associated with marginal cross-
resistance to GrB/scFvMEL.
Effects of Pretreatment with GrB/scFvMEL on
Radiosensitivity in Human Melanoma A375-M Cells
To determine if induction of apoptosis by GrB/scFvMEL
can impact the sensitivity of melanoma cells to external beam
ionizing radiation, A375, A375DR, and antigen-negative
SKBR3 cells were first pretreated with 10 nM GrB/scFvMEL
for 16 hours; the cells were then irradiated and plated for
clonogenic cell survival. Figure 7 shows that GrB/scFvMEL
treatment suppressed the clonogenic survival of both A375
and A375DR cells. The number of surviving colonies at
radiation doses of 2, 4, and 6 Gy was reduced from approx-
imately 34.8 ± 0.23%, 16.0 ± 0.06%, and 5.6 ± 0.55%, respec-
tively, in the A375 radiation-alone control group to 23.1 ±
1.59%, 8.2 ± 0.49%, and 2.8 ± 0.52% in the GrB/scFvMEL
plus radiation treatment group, respectively (Figure 7A,
Table 3A). The observed sensitization was statistically signif-
icant (P < .05) at 2, 4, and 6 Gy dosage groups. After the
treatment of A375DR cells with irradiation alone, colony
survival at doses of 4 and 6 Gy was 13.8 ± 0.32% and 6.9 ±
0.64%, respectively, compared to 9.4 ± 0.29% and 2.8 ±
0.12%, respectively, in the groups cotreated with GrB/
scFvMEL and radiation (Figure 7B, Table 3B). The observed
sensitization in the A375DR groups was statistically signifi-
cant with P < .05 at 4 and 6 Gy, respectively. However, no
statistically significant sensitization was observed in antigen-
negative SKBR3 cells treated with irradiation compared
with GrB/scFvMEL–treated cells followed by irradiation at
2, 4, and 6 Gy (P > .05) (Figure 7C, Table 3C). Therefore,
treatment with GrB/scFvMEL sensitizes both antigen-positive
A375 and A375DR cells that are resistant to ionizing radiation.
This radiosensitization appears to be dependent on the ex-
pression of the gp240 antigen because we did not observe
radiation sensitization with antigen-negative cells.
Effect of GrB/scFvMEL on the Metastatic Potential
of A375DR Cells
We then examined whether the GrB/scFvMEL fusion con-
struct might affect the metastatic potential of melanoma cells
because cellular apoptotic posture is one of the factors that
is known to be responsible for mediating cellular invasion
and metastatic potential [2,3,29,30]. We studied the effects
of GrB/scFvMEL on the ability of A375DR cells to invade a
matrix of a reconstituted basement membrane (Matrigel).
A375DR cells spontaneously form cell aggregates in Matri-
gel when prepared by the hanging-drop technique. A375DR
cells actively leave the aggregate and invade Matrigel prepa-
tion at 4 and 6 days (Figure 8A). The densities of cells in-
vading into Matrigel surrounding the aggregates were ana-
lyzed by AlphaEaseFC software (Alpha Innotech), and per-
cent invasion was calculated based on the cell densities
of two groups and standardized by the value of the non-
treatment control group as 100% invasion. The treatment of
A375DR cells with GrB/scFvMEL inhibits the A375DR in-
vasion of Matrigel. The capability of the invasion of cells
Table 2. Comparison of the Cytotoxic Effects of GrB/scFvMEL and DOX on
Parental A375 Cells and A375DR Sublines.
Cells IC50 (nM)
DOX GrB/scFvMEL
A375 0.5 ± 0.19 14.5 ± 3.93
A375DR 200.0 ± 16.28 63.6 ± 4.01
Resistance index* 400.0 4.5
*Resistance index = (IC50 on A375DR) / (IC50 on A375).
Figure 7. Treatment with GrB/scFvMEL sensitizes melanoma cells to ionizing
radiation. Radiosensitization by GrB/scFvMEL was based on clonogenic cell
survival assays. A375 (A), A375DR (B), and SKBR3-HP (C) cells were pre-
treated with GrB/scFvMEL (10 nM for 16 hours), the drug was washed off,
and cells were irradiated at various doses and plated for clonogenic cell
survival assay. Observed sensitizations were statistically significant at 2, 4,
and 6 Gy dosage groups on A375 cells (P < .05) and at 4 and 6 Gy dosage
groups on A375DR cells (P < .05 and .005, respectively). No statistically
significant sensitization was observed in gp240 antigen–negative SKBR3
cells (P > 0.05).
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significantly decreased to 50.0 ± 2.89% at 4 days and to 45.0
± 1.16% at 6 days (Figure 8, A and B).
In Vivo Animal Studies of GrB/scFvMEL (A375-M
Xenograft Model)
We first examined the internalization or localization of the
GrB/scFvMEL fusion construct in mice bearing A375-M xeno-
graft tumors. After GrB/scFvMEL administration 24 hours
later, mice were sacrificed, and representative tissue sec-
tions were removed, formalin-fixed and stained by H&E, and
detected by either anti-GrB antibody or anti-scFvMEL anti-
body. Localization or internalization of GrB/scFvMEL was ob-
served in tumor tissues (Figure 9).
To examine the in vivo antitumor effects of GrB/scFvMEL,
studies were performed on A375-M human melanoma tumor
xenografts. Mice bearing the tumors were treated (intra-
venously through the tail vein) five times, every other day,
with either GrB/scFvMEL or saline. Saline treatment control
group tumors increased 24-fold (from 50 to 1200 mm3) over
28 days. In contrast, GrB/scFvMEL– treated tumors in-
creased four-fold (from 50 to 200 mm3) (Figure 10A). The
GrB/scFvMEL fusion construct demonstrated impressive
antitumor activity. Tumor tissue nuclei were stained by
TUNEL assay. The results clearly demonstrated that tumor
tissues displayed apoptotic nuclei in the GrB/scFvMEL treat-
ment group (Figure 10B).
Discussion
The human serine protease granzyme B (GrB) is a power-
ful intracellular mediator of cellular apoptotic cascades and
has been identified as one of the primary methods that
regulatory immune cells (macrophages, NK cells, cytotoxic
T cells, and dendritic cells) employ to destroy target cells
[31–38]. This enzyme provides multimodal apoptosis ac-
tivation through both caspase-dependent and caspase-
ndependent pathways [39]. Our study was the first to
describe a novel fusion construct of either an antibody [18]
or a growth factor [40] containing GrB, which redirects this
enzyme specifically to antigen- or receptor-expressing tar-
get cells and potentially describes a new class of targeted
therapeutic agents composed of human cytotoxic proteins
fused to tumor-targeting molecules.
The salient finding of this study is that the antimelanoma
GrB/scFvMEL fusion construct specifically targets human
melanoma cells expressing the gp240 cell surface antigen.
This construct appears to be cytotoxic at nanomolar levels
and has a cytotoxicity profile similar to that of a fusion toxin
containing the highly cytotoxic plant toxin gelonin (rGel).
Treatment of DOX-resistant tumor cells demonstrated only
a modest increase in the IC50 of the GrB/scFvMEL fusion
construct. This observation is in line with that of Classen
et al. [41], who found that GrB-induced cleavages of PARP
and caspases were similar in CEM cells that are sensitive
and resistant to various chemotherapeutic agents.
Numerous cellular and molecular events appear to control
tumor cell invasion and metastatic spread [3,42,43]. Highly
metastatic cells appear to exhibit a higher resistance to
apoptosis compared to their poorly disseminated counter-
parts [2], and we reason that a pharmacological agent acting
solely through apoptotic activation would decrease meta-
static spread. Our data appear to demonstrate that the GrB/
scFvMEL construct is capable of suppressing metastatic
spread in an in vitro (Matrigel) assay, and studies are now on-
going to determine whether this agent can suppress metas-
tases in a highly metastatic melanoma xenograft model [44].
Similarly, apoptotic mechanisms also appear to be respon-
sible for mediating the response of tumor cells to ionizing
radiation [45–48], and agents that activate caspases and
other proapoptotic events appear to sensitize cells to radio-
therapy. Our studies indicate that coadministration of the
GrB/scFvMEL fusion construct can have a modest cell-
specific impact on augmenting the response of tumor cells
to X-irradiation.
In addition to its ability to sensitize tumor cells to radio-
therapy, we found that this construct also appeared to be
highly synergistic with virtually all classes of chemothera-
peutic agents tested. This suggests a broad applicability of
this agent in combination with conventional chemotherapy.
Xenograft model studies are ongoing also to determine
whether this agent is capable of augmenting nonspecific
toxicity as well as antitumor effects.
Normally, GrB requires PFN, but the fusion construct pro-
vides both cell specificity as well as a non-PFN requiring in-
ternalization route. The presence of free PFN in disease
states could potentially make the construct kill nontarget
cells by providing indiscriminant entry into normal cells.
Our previous data suggest that the addition of PFN to non-
target cells exposed to GrB/scFvMEL results in significant
Table 3A. Clonogenic Survival (% Survival) of A375 Cells Treated with Irra-
diation Alone (Control) Versus Irradiation and Treatment with GrB/scFvMEL.
0 Gy 2 Gy 4 Gy 6 Gy
Control 100 34.8 ± 0.23 16.0 ± 0.06 5.6 ± 0.55
GrB/scFvMEL 100 23.1 ± 1.59 8.2 ± 0.49 2.8 ± 0.52
P >.05 <.05* <.05* <.05*
*Significant difference.
Table 3B. Clonogenic Survival (% Survival) of A375DR Cells Treated with Irra-
diation Alone (Control) Versus Irradiation and Treatment with GrB/scFvMEL.
0 Gy 2 Gy 4 Gy 6 Gy
Control 100 33.4 ± 0.09 13.8 ± 0.32 6.9 ± 0.64
GrB/scFvMEL 100 34.0 ± 1.07 9.4 ± 0.29 2.8 ± 0.12
P >.05 >.05 <.05* <.05*
*Significant difference.
Table 3C. Clonogenic Survival (% Survival) of SKBR3-HP Cells Treated with
Irradiation Alone (Control)Versus Irradiation and Treatment with GrB/scFvMEL.
0 Gy 2 Gy 4 Gy 6 Gy
Control 100 59.8 ± 6.90 12.5 ± 4.45 3.4 ± 0.13
GrB/scFvMEL 100 55.9 ± 0.27 12.2 ± 1.43 4.1 ± 0.23
P >.05 >.05 >.05 >.05
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toxicity [18]. There are several diseases indicating that a sig-
nificantly higher expression of PFN is present in the periph-
eral blood circulation [49,50]. This presents the possibility of
causing nonspecific toxicity. The targeted delivery of GrB into
melanoma cells by scFvMEL makes this fusion construct ef-
fective on tumor (not nontarget) cells.
It is surprising that the GrB construct is as active as tox-
ins, which means that GrB is superior to most other toxins
as a therapeutic agent for human cancer because GrB is
a human protein. Humans are supposed to have a strong
immunologic tolerance against endogenous GrB; a hu-
moral or cellular immune response against GrB should not
occur. Toxins such as rGel, Pseudomonas exotoxin, or Ricin
toxin A chain, which are derived from plants, are highly
Figure 9. GrB/scFvMEL is localized or internalized in tumor tissues. Mice
bearing A375-M xenograft tumors were administered intravenously GrB/
scFvMEL (37.5 mg/kg). Twenty-four hours after the last dose, animals were
sacrificed, and tumor tissues were removed, fixed, and stained by immuno-
histochemical staining for GrB/scFvMEL detected by either anti-GrB or anti-
scFvMEL antibody. Localization and internalization of GrB/scFvMEL were
observed in tumor tissues in the treatment group, but not in the control group.
Figure 8. GrB/scFvMEL inhibits A375DR cell invasion of Matrigel. A375DR cell aggregates were prepared as described under Materials and Methods. Cell
aggregates were transferred over the Matrigel cushion and then overlaid with an additional 100 l of Matrigel. The aggregates into Matrigel were covered with 400 l
of culture medium in the absence or presence of GrB/scFvMEL (50 nM). The aggregates were then observed daily under a light microscope (A). A375DR cells
actively leave the aggregate and invade Matrigel preparation at 4 and 6 days. The treatment of A375DR cells with GrB/scFvMEL inhibits the A375DR invasion of
Matrigel at 4 and 6 days. The densities of cells invading into Matrigel surrounding the aggregates were analyzed by AlphaEaseFC software, and percent invasion
was calculated based on the cell densities of the two groups and standardized by the value of the nontreatment control group as 100% invasion (B).
Figure 10. GrB/scFvMEL demonstrates antitumor activity in a xenograft
melanoma model by inducing apoptosis in tumor tissues. (A) Antitumor effect
of GrB/scFvMEL on A375-M xenograft tumors. Female athymic (nu/nu) mice,
6 to 8 weeks of age, were injected subcutaneously on the right flank with 3 
106 log-phase A375-M cells, and tumors were allowed to establish. Once
tumors had reached a measurable size (f50 mm3), animals were admin-
istered intravenously with either saline (control) or the GrB/scFvMEL fusion
construct five times, every other day (37.5 mg/kg, total dose). Animals were
monitored and tumors were measured for an additional 28 days. Saline-
treated control tumors increased 24-fold (from 50 to 1200 mm3) over
28 days. In contrast, GrB/scFvMEL– treated tumors increased four-fold (from
50 to 200 mm3). (B) Apoptosis detection in tumor tissue by TUNEL assay.
Mice bearing A375-M xenograft tumors were administered intravenously
GrB/scFvMEL (37.5 mg/kg). Twenty-four hours after the last dose, a group of
animals was sacrificed, and tumor tissues were removed and fixed. Tumor
tissue sections were stained by TUNEL and analyzed under a Nikon Eclipse
TS 100 fluorescent microscope. Tumor tissues displayed highly apoptotic nu-
clei in the treatment group compared to the control group.
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immunogenic in humans [51] and tend to induce drug resis-
tance after several treatments [52]. Because GrB activates
numerous independent cascade events through enzymatic
mechanisms of action, the development of resistance to
GrB is unlikely.
Other studies targeting GrB [53,54] to other tumor cell
types appear to indicate that there is broad applicability for
this as a platform technology. Kurschus et al. reported that
retargeting of GrB to Lewis Y–positive surface receptors
by GrB/dsFv-B3 conjugate could lead to PFN-independent
target cell death with efficacy similar to that of dsFv-B3 tar-
geted Pseudomonas exotoxin fragment 38. The data also
indicated that the activity of GrB was only weakly inhibited
by plasma proteins [54].
The studies demonstrated that the targeted delivery of
GrB can be achieved adequately to kill target cells. The fu-
sion construct GrB/scFvMEL specifically kills gp240-bearing
cells and sensitizes cells to chemotherapy and radiation
therapy. The fusion construct has the potential to reduce
the invasion of tumor cells. This is proof-of-core concept
that targeted/pharmacological control of apoptotic processes
can be achieved. GrB-based immunotoxins should be useful
as a new class of immunotoxins with low immunogenicity
utilizing programmed cell death for therapeutic purposes.
References
[1] Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O,
Nova P, Aglione S, Taillibert S, and Khayat D (2002). Metastatic mela-
noma: chemotherapy. Semin Oncol 29, 427–445.
[2] Glinsky GV and Glinsky VV (1996). Apoptosis and metastasis: a supe-
rior resistance of metastatic cancer cells to programmed cell death.
Cancer Lett 101, 43–51.
[3] Glinsky GV, Glinsky VV, Ivanova AB, and Hueser CJ (1997). Apoptosis
and metastasis: increased apoptosis resistance of metastatic cancer
cells is associated with the profound deficiency of apoptosis execution
mechanisms. Cancer Lett 115, 185–193.
[4] Awada A, Cardoso F, Atalay G, Giuliani R, Mano M, and Piccart MJ
(2003). The pipeline of new anticancer agents for breast cancer treat-
ment in 2003. Crit Rev Oncol Hematol 48, 45–63.
[5] Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C,
Lucas T, Hoermann M, Hollenstein U, Wolff K, and Pehamberger H
(2000). Chemosensitisation of malignant melanoma by BCL2 antisense
therapy. Lancet 356, 1728–1733.
[6] Pak BJ, Lee J, Thai BL, Fuchs SY, Shaked Y, Ronai Z, Kerbel RS, and
Ben David Y (2004). Radiation resistance of human melanoma ana-
lyzed by retroviral insertional mutagenesis reveals a possible role for
dopachrome tautomerase. Oncogene 23, 30–38.
[7] Rockmann H and Schadendorf D (2003). Drug resistance in human
melanoma: mechanisms and therapeutic opportunities. Onkologie 26,
581–587.
[8] Soengas MS and Lowe SW (2003). Apoptosis and melanoma chemo-
resistance. Oncogene 22, 3138–3151.
[9] Kantor RR, Ng AK, Giacomini P, and Ferrone S (1982). Analysis of the
NIH workshop monoclonal antibodies to human melanoma antigens.
Hybridoma 1, 473–482.
[10] Kantor RR, Albino AP, Ng AK, and Ferrone S (1986). Biosynthesis and
intracellular processing of four human melanoma associated antigens.
Cancer Res 46, 5223–5228.
[11] Macey DJ, Denardo SJ, Denardo GL, Goodnight JK, and Unger MW
(1988). Uptake of indium-111– labeled monoclonal antibody ZME-018
as a function of tumor size in a patient with melanoma. Am J Physiol
Imaging 3, 1–6.
[12] Rosenblum MG, Murray JL, Cheung L, Rifkin R, Salmon S, and
Bartholomew R (1991). A specific and potent immunotoxin composed
of antibody ZME-018 and the plant toxin gelonin. Mol Biother 3, 6–13.
[13] Rosenblum MG, Levin B, Roh M, Hohn D, McCabe R, Thompson L,
Cheung L, and Murray JL (1994). Clinical pharmacology and tissue dis-
position studies of 131I-labeled anticolorectal carcinoma human mono-
clonal antibody LiCO16.88.Cancer Immunol Immunother 39, 397–400.
[14] Mujoo K, Cheung L, Murray JL, and Rosenblum MG (1995). Pharmaco-
kinetics, tissue distribution, and in vivo antitumor effects of the anti-
melanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother
40, 339–345.
[15] Rosenblum MG, Cheung L, Mujoo K, and Murray JL (1995). An anti-
melanoma immunotoxin containing recombinant human tumor necrosis
factor: tissue disposition, pharmacokinetic, and therapeutic studies in
xenograft models. Cancer Immunol Immunother 40, 322–328.
[16] Liu Y, Cheung LH, Marks JW, and Rosenblum MG (2004). Recombinant
single-chain antibody fusion construct targeting human melanoma cells
and containing tumor necrosis factor. Int J Cancer 108, 549–557.
[17] Rosenblum MG, Cheung LH, Liu Y, and Marks JW III (2003). Design,
expression, purification, and characterization, in vitro and in vivo, of
an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
Cancer Res 63, 3995–4002.
[18] Liu Y, Cheung LH, Hittelman WN, and Rosenblum MG (2003). Targeted
delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies
describing a novel class of recombinant highly cytotoxic agents. Mol
Cancer Ther 2, 1341–1350.
[19] Rosenblum MG, Cheung L, Murray JL, and Bartholomew R (1991).
Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): im-
provement of cytotoxicity and reduction of cellular resistance. Cancer
Commun 3, 21–27.
[20] Rosenblum MG, Cheung L, Kim SK, Mujoo K, Donato NJ, and Murray
JL (1996). Cellular resistance to the antimelanoma immunotoxin ZME-
gelonin and strategies to target resistant cells. Cancer Immunol Immun-
other 42, 115–121.
[21] Rosenblum MG, Marks JW, and Cheung LH (1999). Comparative
cytotoxicity and pharmacokinetics of antimelanoma immunotoxins con-
taining either natural or recombinant gelonin. Cancer Chemother Phar-
macol 44, 343–348.
[22] Smyth MJ and Trapani JA (1995). Granzymes: exogenous proteinases
that induce target cell apoptosis. Immunol Today 16, 202–206.
[23] Yagita H, Nakata M, Kawasaki A, Shinkai Y, and Okumura K (1992).
Role of perforin in lymphocyte-mediated cytolysis. Adv Immunol 51,
215–242.
[24] Shi L, Kraut RP, Aebersold R, and Greenberg AH (1992). A natural killer
cell granule protein that induces DNA fragmentation and apoptosis.
J Exp Med 175, 553–566.
[25] Orth K, Chinnaiyan AM, Garg M, Froelich CJ, and Dixit VM (1996). The
CED-3/ICE– like protease Mch2 is activated during apoptosis and
cleaves the death substrate lamin A. J Biol Chem 271, 16443–16446.
[26] Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K,
Browne KA, and Trapani JA (2000). Initiation of apoptosis by granzyme
B requires direct cleavage of bid, but not direct granzyme B–mediated
caspase activation. J Exp Med 192, 1403–1414.
[27] Trapani JA, Browne KA, Smyth MJ, and Jans DA (1996). Localization
of granzyme B in the nucleus. A putative role in the mechanism of cyto-
toxic lymphocyte–mediated apoptosis. J Biol Chem 271, 4127–4133.
[28] Osborne CK, Hobbs K, and Clark GM (1985). Effect of estrogens and
antiestrogens on growth of human breast cancer cells in athymic nude
mice. Cancer Res 45, 584–590.
[29] Simstein R, Burow M, Parker A, Weldon C, and Beckman B (2003).
Apoptosis, chemoresistance, and breast cancer: insights from the
MCF-7 cell model system. Exp Biol Med (Maywood) 228, 995–1003.
[30] Rubio N, Espana L, Fernandez Y, Blanco J, and Sierra A (2001). Meta-
static behavior of human breast carcinomas overexpressing the Bcl-
x(L) gene: a role in dormancy and organospecificity. Lab Invest 81,
725–734.
[31] Kraan MC, Haringman JJ, Weedon H, Barg EC, Smith MD, Ahern MJ,
Smeets TJ, Breedveld FC, and Tak PP (2004). T cells, fibroblast-like
synoviocytes, and granzyme B+ cytotoxic cells are associated with joint
damage in patients with recent onset rheumatoid arthritis. Ann Rheum
Dis 63, 483–488.
[32] Jose MD, Ikezumi Y, van Rooijen N, Atkins RC, and Chadban SJ
(2003). Macrophages act as effectors of tissue damage in acute renal
allograft rejection. Transplantation 76, 1015–1022.
[33] Humbert M, Devergne O, Cerrina J, Rain B, Simonneau G, Dartevelle P,
Duroux P, Galanaud P, and Emilie D (1992). Activation of macrophages
and cytotoxic cells during cytomegalovirus pneumonia complicating
lung transplantations. Am Rev Respir Dis 145, 1178–1184.
[34] MacDonald G, Shi L, Vande VC, Lieberman J, and Greenberg AH
(1999). Mitochondria-dependent and -independent regulation of Gran-
zyme B– induced apoptosis. J Exp Med 189, 131–144.
[35] Spaeny-Dekking EH, Hanna WL, Wolbink AM, Wever PC, Kummer AJ,
134 Antimelanoma Immunotoxin Containing Granzyme B Liu et al.
Neoplasia . Vol. 8, No. 2, 2006
Swaak AJ, Middeldorp JM, Huisman HG, Froelich CJ, and Hack CE
(1998). Extracellular granzymes A and B in humans: detection of native
species during CTL responses in vitro and in vivo. J Immunol 160,
3610–3616.
[36] Smyth MJ, O’Connor MD, and Trapani JA (1996). Granzymes: a variety
of serine protease specificities encoded by genetically distinct sub-
families. J Leukoc Biol 60, 555–562.
[37] Smyth MJ, Browne KA, Thia KY, Apostolidis VA, Kershaw MH, and
Trapani JA (1994). Hypothesis: cytotoxic lymphocyte granule serine
proteases activate target cell endonucleases to trigger apoptosis. Clin
Exp Pharmacol Physiol 21, 67–70.
[38] Clement MV, Haddad P, Soulie A, Legros-Maida S, Guillet J, Cesar E,
and Sasportes M (1990). Involvement of granzyme B and perforin gene
expression in the lytic potential of human natural killer cells. Res Im-
munol 141, 477–489.
[39] Wowk ME and Trapani JA (2004). Cytotoxic activity of the lymphocyte
toxin granzyme B. Microbes Infect 6, 752–758.
[40] Liu Y, Cheung LH, Thorpe P, and Rosenblum MG (2003). Mechanistic
studies of a novel human fusion toxin composed of vascular endothe-
lial growth factor (VEGF)121 and the serine protease granzyme B:
directed apoptotic events in vascular endothelial cells. Mol Cancer Ther
2, 949–959.
[41] Classen CF, Falk CS, Friesen C, Fulda S, Herr I, and Debatin KM (2003).
Natural killer resistance of a drug-resistant leukemia cell line, mediated
by up-regulation of HLA class I expression. Haematologica 88, 509–521.
[42] Volm M and Koomagi R (1999). The implications of proliferation and
apoptosis for lung cancer metastasis. Oncol Rep 6, 373–376.
[43] Mustika R, Budiyanto A, Nishigori C, Ichihashi M, and Ueda M (2005).
Decreased expression of Apaf-1 with progression of melanoma. Pig-
ment Cell Res 18, 59–62.
[44] Mujoo K, Cheung L, Murray JL, and Rosenblum MG (1995). Pharmaco-
kinetics, tissue distribution, and in vivo antitumor effects of the antime-
lanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother 40,
339–345.
[45] Schafer J, Bachtler J, Engling A, Little JB, Weber KJ, and Wenz F
(2002). Suppression of apoptosis and clonogenic survival in irradiated
human lymphoblasts with different TP53 status. Radiat Res 158,
699–706.
[46] UchidaH, Shinoura N, Kitayama J,Watanabe T, NagawaH, andHamada
H (2002). Caspase-8 gene transduction augments radiation-induced
apoptosis in DLD-1 cells. Biochem Biophys Res Commun 292,
347–354.
[47] Rocha S, Soengas MS, Lowe SW, Glanzmann C, Fabbro D,Winterhalter
K, Bodis S, and Pruschy M (2000). Protein kinase C inhibitor and
irradiation-induced apoptosis: relevance of the cytochrome c–mediated
caspase-9 death pathway. Cell Growth Differ 11, 491–499.
[48] Belka C, Heinrich V, Marini P, Faltin H, Schulze-Osthoff K, Bamberg M,
and Budach W (1999). Ionizing radiation and the activation of caspase-
8 in highly apoptosis-sensitive lymphoma cells. Int J Radiat Biol 75,
1257–1264.
[49] Prpic ML, Kastelan M, Gruber F, Laskarin G, Sotosek V, Strbo N, Zamolo
G, Zauhar G, and Rukavina D (2004). Perforin expression in peripheral
blood lymphocytes and skin-infiltrating cells in patients with lichen pla-
nus. Br J Dermatol 151, 433–439.
[50] Rieux-Laucat F, Le Deist F, and De Saint BG (2005). Autoimmune lym-
phoproliferative syndrome and perforin. N Engl J Med 352, 306–307.
[51] Kreitman RJ (1999). Immunotoxins in cancer therapy. Curr Opin Immu-
nol 11, 570–578.
[52] McGrath MS, Rosenblum MG, Philips MR, and Scheinberg DA (2003).
Immunotoxin resistance in multidrug resistant cells. Cancer Res 63,
72–79.
[53] Zhao J, Zhang LH, Jia LT, Zhang L, Xu YM, Wang Z, Yu CJ, Peng WD,
Wen WH, Wang CJ, et al. (2004). Secreted antibody/granzyme B
fusion protein stimulates selective killing of HER2-overexpressing
tumor cells. J Biol Chem 279, 21343–21348.
[54] Kurschus FC, Kleinschmidt M, Fellows E, Dornmair K, Rudolph R, Lilie
H, and Jenne DE (2004). Killing of target cells by redirected granzyme
B in the absence of perforin. FEBS Lett 562, 87–92.
Antimelanoma Immunotoxin Containing Granzyme B Liu et al. 135
Neoplasia . Vol. 8, No. 2, 2006
